Alectinib Treatment of ALK Positive Non Small Cell Lung Cancer Patients with Brain Metastases: Our Clinical Experience

1. WHO Statistics. http://www.who.int/mediacentre/factsheets/fs297/en/ (accessed 21 December 2017).Search in Google Scholar

2. Salomon B, Varella-Garcia M and Camidge DR. ALK gene rearrangements a new therapeutic target in a molecularly defined subset of non-smal cell lung cancer. J Thorac Oncol 2009; 4: 1450–1454.10.1097/JTO.0b013e3181c4dedb20009909Search in Google Scholar

3. Soda M. Choi YL, Enomoto M. et al. Identification of the transforming EML4-ALK fusion gene in NSCLC. Nature 2007; 448: 561–566.10.1038/nature0594517625570Search in Google Scholar

4. Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies ocogenic kinases in lung cancer. Cell 2007; 131: 1190–1203.10.1016/j.cell.2007.11.02518083107Search in Google Scholar

5. Kris M, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 2014; 311: 1998–2006.10.1001/jama.2014.3741416305324846037Search in Google Scholar

6. Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with NSCLC who harbor EMLA-4-ALK. J Clin Oncol 2009; 27: 4247–4253.10.1200/JCO.2009.22.6993274426819667264Search in Google Scholar

7. Kwak EL, Bang YJ, Camidge DR, et al. Anaplstic lymphoma kinase inhibition in NSCLC. N Engl J Med 2010; 363: 1693–1703.10.1056/NEJMoa1006448301429120979469Search in Google Scholar

8. Passaro K, Lazzari C, Karachaliou N et al. Personalized treatment in advanced ALK-positive NSCLC; from bench to clinical practice. Onco Targets Ther.2016; 9: 6361–6376.10.2147/OTT.S98347507470327799783Search in Google Scholar

9. Costa DR, Kobayashi S, Pandya SS, et al. CSF concentration of anplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol 2011; 29: c443-c445.10.1200/JCO.2010.34.131321422405Search in Google Scholar

10. Mok T, Camidge D. R., Gadgeel S. M.et al. Updated overall survival and final progression-free survival data for patients with treatment-naïve advanced ALK-positive non-small-cell lung cancer in the Annals of Oncology ALEX study 2020 doi: https://doi.org/10.1016/j.annonc.2020.Search in Google Scholar

11. Metro G, Lunardi G, Floridi P, et al. CSF concentration of crizotinib in two ALK-positive NSCLC patients with CNS metastases deriving clinical benefit from treatment. J Thorac Oncol 2015;10:c26-c27.10.1097/JTO.000000000000046825898960Search in Google Scholar

12. Ricciuti B, De Gioglio A, Mecca c, et al. Precision medicine against ALK positive NSCLC: beyond crizotinib. Med Oncol 2018; 35: 72.10.1007/s12032-018-1133-429666949Search in Google Scholar

13. Rossi A, Alectinib for ALK-positive NSCLC. Exp Rev Clin Pharmacol 2016; 9: 1005–1013.Search in Google Scholar

14. Vavalia T, Novello S. Alectinib in the treatment of ALK-positive non-small cell lung cancer: an update on its properties, efficacy, safety and place in therapy. Ther Adv Med Oncol 2018, Vol. 10: 1–12.10.1177/1758835918789364Search in Google Scholar

15. Kodama T, Hasegawa M, Takanashi K, et al. Antitumor activity of selective ALK inhibitor alec-tinib in models of intracraneal metástasis. Cáncer Chemother Pharmacol 2014; 74: 1023–1028.10.1007/s00280-014-2578-6Search in Google Scholar

16. Katayama R, Sakashhita T, Yanagitani N, et al. P-glycoprotein mediates ceritinib resistance in anaplastic lymphoma kinase-rearranged NSCLC. Bio Medicine 2016; 3: 54–66.Search in Google Scholar

17. Novello S, Mazieres J, oh IJ, et al. Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive NSCLC: results from the phase III ALUR study. Ann Oncol 2018; 29: 1409–1416.10.1093/annonc/mdy121Search in Google Scholar

18. Metro G, Lunardi G, Bennati C, et al Alectinib’s activity against CNS metastases from ALK-positive NSCLC a single institution case series. J Neuro Oncol 2016; 129: 355–361.10.1007/s11060-016-2184-zSearch in Google Scholar

19. Gainor JF, Sherman CA, Willoughby K, et al. Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crisotinib and ceritinib. J Thorac Oncol 2015; 10: 232–236.10.1097/JTO.0000000000000455Search in Google Scholar

20. Ou SH, Klempner SJ, Azada MC, et al. Radiation necrosis presenting as pseudoprogression (PsP) during alectinib treatment of previously radiated brain metastases in ALK-positive NSCLC implications for disease assessment and management Lung cancer 2015; 88: 355–359.Search in Google Scholar

21. Norsdal RA, Wong CS. Molecular targets in radiation-induced blood-brain barrier disruption Int J Radiat Oncol Biol Phs 2005; 52: 279–287.Search in Google Scholar

22. Qin DX, Zheng R, Tang J et al Influence of radiation on the blood-brain barrier permeability changes and optimum time of chemotherapy. Int J Radiat Oncol Biol Phs 1990; 19: 1507–1510.10.1016/0360-3016(90)90364-PSearch in Google Scholar

23. Khalifa J, Amini A, Popat S et al Brain metastases from NSCLC: radiation therapy in the era of targeted therapies Jour of Thorac Oncol 2016; 10: 1627–1643.10.1016/j.jtho.2016.06.00227343440Search in Google Scholar

24. Tran PN and Klempner SJ. Focus on alectinib and competitor compounds for second line therapy in ALK-rearranged NSCLC. Front Med (Lausanne) 2016; 3: 65.10.3389/fmed.2016.00065512785127965961Search in Google Scholar

25. Gadgeel SM, Shaw AT, Barlesi f, et al. Cumulative incidence rates for CNS and non CNS progression in two phase II studies of alectinib in ALK-positive NSCLC Br J Cancer 2018; 118: 38–42.Search in Google Scholar

26. Chuang YC, Huang BY, Chang HW, Yang CN. Molecular modeling of ALK L1198F and/or G1202R mutations to determine differential crizotinib sensitivity. Sci Rep. 2019; 9: 11390.10.1038/s41598-019-46825-1668480131388026Search in Google Scholar

27. Camidge DR, Dziadziuszko R, Peters S, et al. Updated efficacy and safety data and impact of EML4-ALK fusion variant on the efficacy of alectinib in untreated ALK positive advanced non–small cell lung cancer in the global phase III ALEX study. J Thorac Oncol. 2019; 14: 1233–1243.10.1016/j.jtho.2019.03.00730902613Search in Google Scholar

28. Dagogo-Jack I, Rooney M, Lin JJ, et al. Treatment with next-generation ALK inhibitors fuels plasma ALK mutation diversity. Clin Cancer Res. 2019; 25: 6662–6670.10.1158/1078-0432.CCR-19-1436685895631358542Search in Google Scholar

29. Shaw AT, Solomon BJ, Besse B, et al. ALK resistance mutations and efficacy of lorlatinib in advanced anaplastic lymphoma kinase-positive non–small-cell lung cancer. J Clin Oncol. 2019; 37: 1370–1379.10.1200/JCO.18.02236654446030892989Search in Google Scholar

• Retraction Note
• New Developments in Publishing Related to Authorship
• Retraction Note